Peptide Database

Category: FAT LOSS / LEAN MUSCLE

Description

Best blend for overall body and anti-aging mixed with heavy weight loss needs

Specifications

Amount in Vial: 15mg

BAC Water: 1ml

Amount per Unit: 0.15mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1.5mg to 4.5mg (10 to 30 units)

Frequency: 5 days on 2 off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.15mg per unit

Category: FAT LOSS / LEAN MUSCLE

Description

Great blend for athlete trying to put on lean muscle tissue and fat to muscle conversion

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2mg to 4mg (20 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: FAT LOSS / LEAN MUSCLE

Description

Great blend for muscle retention, anti aging and losing fat in stubborn spots

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2mg to 4mg (20 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: FAT LOSS / LEAN MUSCLE

Description

Best blend for the athlete looking to compete, recovery and anti aging while adding lean muscle mass

Specifications

Amount in Vial: 8mg

BAC Water: 1ml

Amount per Unit: 0.08mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1.6mg to 3.2mg (20 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.08mg per unit

Category: FAT LOSS / LEAN MUSCLE

Description

Bulking blend to increase muscle mass while increasing appetite

Specifications

Amount in Vial: 13mg

BAC Water: 1ml

Amount per Unit: 0.13mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2.6mg to 5.2mg (20 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.13mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. as a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to glp-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that glp-1 action restricted to the brain alone still produces significant food intake reduction. phase 3 clinical trials with glp-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 2mg

BAC Water: 1ml

Amount per Unit: 0.02mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (12 to 125 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.02mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. as a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to glp-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that glp-1 action restricted to the brain alone still produces significant food intake reduction. phase 3 clinical trials with glp-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (5 to 50 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. as a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to glp-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that glp-1 action restricted to the brain alone still produces significant food intake reduction. phase 3 clinical trials with glp-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (5 to 50 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 (glucagon-like peptide-1) is an incretin hormone naturally released by the gut after eating. as a receptor agonist, it enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and signals the brain's hypothalamus to reduce appetite — all through binding to glp-1 receptors expressed in the pancreas, brain, gut, and adipose tissue. brain-mediated appetite suppression is now considered the primary driver of its weight loss effects, with preclinical research showing that glp-1 action restricted to the brain alone still produces significant food intake reduction. phase 3 clinical trials with glp-1 agonists have demonstrated mean body weight reductions of approximately 15% over 68 weeks, with approximately 50% of participants achieving 15% or more weight loss. common research side effects include nausea, vomiting, and constipation, particularly during dose titration — which is why starting doses are low and titrated upward gradually. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 20mg

BAC Water: 4ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (5 to 50 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 dual agonist peptides target both the glp-1 receptor and the gip (glucose-dependent insulinotropic polypeptide) receptor simultaneously. glp-1 and gip receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. the dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single glp-1 agonism alone. phase 3 clinical trials with dual gip/glp-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. gastrointestinal side effects are typically milder than with glp-1 mono-agonists due to the complementary gip receptor mechanism. for research and educational purposes only. not fda-approved for all formulations. consult a qualified healthcare professional.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 10mg (25 to 100 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 dual agonist peptides target both the glp-1 receptor and the gip (glucose-dependent insulinotropic polypeptide) receptor simultaneously. glp-1 and gip receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. the dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single glp-1 agonism alone. phase 3 clinical trials with dual gip/glp-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. gastrointestinal side effects are typically milder than with glp-1 mono-agonists due to the complementary gip receptor mechanism. for research and educational purposes only. not fda-approved for all formulations. consult a qualified healthcare professional.

Specifications

Amount in Vial: 30mg

BAC Water: 3ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 15mg (25 to 150 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 dual agonist peptides target both the glp-1 receptor and the gip (glucose-dependent insulinotropic polypeptide) receptor simultaneously. glp-1 and gip receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. the dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single glp-1 agonism alone. phase 3 clinical trials with dual gip/glp-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. gastrointestinal side effects are typically milder than with glp-1 mono-agonists due to the complementary gip receptor mechanism. for research and educational purposes only. not fda-approved for all formulations. consult a qualified healthcare professional.

Specifications

Amount in Vial: 50mg

BAC Water: 3ml

Amount per Unit: 0.17mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 15mg (15 to 90 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.17mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-1 dual agonist peptides target both the glp-1 receptor and the gip (glucose-dependent insulinotropic polypeptide) receptor simultaneously. glp-1 and gip receptors are co-expressed in the brain, pancreatic beta cells, adipose tissue, and other metabolic tissues. activating both pathways produces synergistic — not merely additive — metabolic effects, because each receptor pathway converges on overlapping cellular machinery. the dual mechanism results in greater appetite suppression, enhanced insulin secretion, better glycemic control, and more pronounced fat oxidation compared to single glp-1 agonism alone. phase 3 clinical trials with dual gip/glp-1 agonists showed average body weight reductions of 20–21% at maximum doses, with 91% of participants achieving at least 5% weight loss. gastrointestinal side effects are typically milder than with glp-1 mono-agonists due to the complementary gip receptor mechanism. for research and educational purposes only. not fda-approved for all formulations. consult a qualified healthcare professional.

Specifications

Amount in Vial: 60mg

BAC Water: 3ml

Amount per Unit: 0.2mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 15mg (12.5 to 75 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.2mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-3 class peptides are triple receptor agonists targeting glp-1, gip, and glucagon receptors simultaneously. adding glucagon receptor activation to the dual glp-1/gip mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. the three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. phase 3 data has since reported up to 28.7% weight loss. the glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. gastrointestinal tolerability is generally comparable to dual agonists. for research and educational purposes only. independent purity testing warning (june 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per chainalysis reporting. source only from vendors providing current, batch-specific hplc certificates of analysis.

Specifications

Amount in Vial: 12mg

BAC Water: 1.2ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2mg to 12mg (20 to 120 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Glp-3 class peptides are triple receptor agonists targeting glp-1, gip, and glucagon receptors simultaneously. adding glucagon receptor activation to the dual glp-1/gip mechanism introduces a third lever: glucagon signaling increases energy expenditure and hepatic fat metabolism, which further amplifies the fat-reduction signal beyond what dual agonists achieve. the three receptor pathways work synergistically across the brain, liver, pancreas, and adipose tissue. phase 2 clinical research on triple agonists showed mean body weight reduction of 24.2% at 48 weeks, with participants still losing weight at study end — indicating a plateau had not yet been reached. phase 3 data has since reported up to 28.7% weight loss. the glucagon component also increases energy expenditure, which researchers propose may explain the energy and cognitive benefits often reported alongside weight reduction. gastrointestinal tolerability is generally comparable to dual agonists. for research and educational purposes only. independent purity testing warning (june 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per chainalysis reporting. source only from vendors providing current, batch-specific hplc certificates of analysis.

Specifications

Amount in Vial: 24mg

BAC Water: 2.4ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2mg to 12mg (20 to 120 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2 MG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Survodutide is a dual agonist of the glp-1 and glucagon receptors — a distinct mechanism from the glp-1/gip dual agonist class. where gip receptor activation enhances insulin sensitivity and fat storage regulation, glucagon receptor activation increases hepatic glucose output and energy expenditure. this pairing makes survodutide particularly relevant in research focused on metabolic liver disease, including non-alcoholic fatty liver disease (nafld) and metabolic dysfunction-associated steatohepatitis (mash), in addition to weight loss. its phase 3 trial results are pending as of 2025. the glucagon component is associated with increased resting energy expenditure, which may explain the chronic fatigue benefits observed in preliminary research. for research and educational purposes only.

Specifications

Amount in Vial: 6mg

BAC Water: 1ml

Amount per Unit: 0.06mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 600mcg to 4.5mg (10 to 75 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 600MCG

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.06mg per unit

Category: WEIGHT MANAGEMENT

Description

Stimulates lyposis (breakdown of fat) does not enhance hunger or blood sugar levels great to stack with other peptides

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1mg (20 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted Before Bed or Upon Waking (Fasted Cardio)

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: WEIGHT MANAGEMENT

Description

Cagrilintide is a long-acting amylin analogue — amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells. it binds amylin receptors in the hypothalamus and brainstem to reduce food intake, slow gastric emptying, and suppress glucagon. its pharmacological half-life allows once-weekly dosing. cagrilintide is most extensively studied in combination with semaglutide (the combination is called cagrisema, developed by novo nordisk). phase 3 redefine-1 trial results showed cagrisema produced approximately 20.4% weight loss — greater than either agent alone — with a new drug application submitted to the fda in december 2025. when added to existing glp-1 protocols, cagrilintide may allow glp-1 dose reduction while maintaining or enhancing weight loss outcomes, potentially reducing dose-dependent nausea. research also suggests amylin receptor activation may independently improve insulin sensitivity beyond its appetite effects. for research and educational purposes only.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 300mcg to 4.5mg (6 to 90 units)

Frequency: Once per week

Timing: Can Be Added To GLP To Reduce That Dosage

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Increases endogenous igf-1 - minimal effects on ghrelin - thermogenic - increase muscle mass

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (10 to 20 units)

Frequency: 5 days on 2 off

Timing: Fasted Before Bed or Upon Waking

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Increases endogenous igf-1 - minimal effects on ghrelin - thermogenic - increase muscle mass

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2mg to 4mg (20 to 40 units)

Frequency: 1 to 2 times per week

Timing: No More Than 4MG Per Week

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Stimulates the release of endogenous growth hormone - increased igf-1 - decrease visceral fat

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (10 to 20 units)

Frequency: 5 days on 2 off

Timing: Taken Before Bedtime

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Stimulates the release of endogenous growth hormone - increased igf-1 - decrease visceral fat

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (10 to 20 units)

Frequency: 5 days on 2 off

Timing: Taken Before Bedtime

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Stimulates the release of endogenous growth hormone - improved muscle strength, growth and repair - anti aging - improved bone density

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 2mg (10 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 2 Hours Before First Meal or Before Bed or Split

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: GROWTH HORMONE RELEASING HORMONE

Description

Stimulates the release of endogenous growth hormone - improved muscle strength, growth and repair - anti aging - improved bone density

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 2mg (10 to 40 units)

Frequency: 5 days on 2 off

Timing: Fasted - 2 Hours Before First Meal or Before Bed or Split

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

Second strongest ghrp - stimulates the release of endogenous growth hormone and ghrelin - promotes muscle growth

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 150mcg to 300mcg (6 to 12 units)

Frequency: As needed

Timing: Multiple Times a Day as Needed Before Meals

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

Third strongest ghrp - stimulates the release of endogenous growth hormone and ghrelin - promotes muscle growth - increased appetite

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 150mcg to 300mcg (6 to 12 units)

Frequency: As needed

Timing: Multiple Times a Day as Needed Before Meals

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

Stimulates the release of endogenous growth hormone, without increase of appetite, cortisol or prolactin - promotes muscle growth

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 200mcg to 300mcg (4 to 6 units)

Frequency: 5 days on 2 off

Timing: Fasted - 30 Minutes Before Each Meal Up To 3 Times A Day

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: GROWTH HORMONE RELEASING PEPTIDE

Description

Most potent ghrp - stimulates release of growth hormone without increase of appetite - promotes muscle growth

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 100mcg (3x day) (4 units)

Frequency: 3 times a day for 20 weeks

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: HUMAN GROWTH HORMONE

Description

Exogenous human growth hormone - muscle growth - bone density - regulates metabolism by promoting lyposis

Specifications

Amount in Vial: 10iu

BAC Water: 1ml

Amount per Unit: 0.1iu per unit

Injection Type: Subcutaneous

Recommended Dose: 2iu to 6iu (20 to 60 units)

Frequency: 5 days on 2 off or 3 days on 1 day off

Timing: Fasted - 45 Minutes Before and After Injection

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1iu per unit

Category: INSULIN LIKE GROWTH FACTOR

Description

Works by binding to igf-1 receptors - builds muscle - burns fat - increased metabolism - muscle recovery and repair

Specifications

Amount in Vial: 1mg

BAC Water: 1ml

Amount per Unit: 0.01mg per unit

Injection Type: Intramuscular

Recommended Dose: 100mcg to 200mcg (10 to 20 units)

Frequency: 5 day on 2 off

Timing: After Meal / Before Gym

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: INSULIN LIKE GROWTH FACTOR

Description

Igf1-des (des(1-3)igf-1) is a naturally occurring truncated variant of insulin-like growth factor 1, lacking the first three n-terminal amino acids. this structural difference makes it approximately 10 times more potent than standard igf-1 at binding igf-1 receptors, because the truncation reduces binding to igf binding proteins (igfbps) that normally regulate igf-1 availability. as a result, a greater proportion of igf1-des reaches free receptor sites. it shares igf-1's core mechanisms: stimulating protein synthesis, promoting satellite cell activation and muscle fiber hypertrophy, increasing glucose uptake in muscle tissue, and supporting fat metabolism. its faster receptor binding and reduced igfbp interference make it particularly relevant in research focused on local muscle tissue effects when administered intramuscularly near target sites. for research and educational purposes only.

Specifications

Amount in Vial: 1mg

BAC Water: 1ml

Amount per Unit: 0.01mg per unit

Injection Type: Intramuscular

Recommended Dose: 100mcg to 200mcg (10 to 20 units)

Frequency: 5 day on 2 off

Timing: After Meal / Before Gym

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: GONADOTROPIN RELEASING HORMONE

Description

Stimulates gonadotropin release - releases lh and fsh promoting the production of testosterone - treats hypogonadism

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg (10 units)

Frequency: Daily

Timing: Run Based on Dr Recommendation for Fertilization

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: GONADOTROPIN RELEASING HORMONE

Description

Stimulates gonadotropin release - releases lh and fsh promoting the production of testosterone - treats hypogonadism

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg (5 units)

Frequency: Daily

Timing: Run Based on Dr Recommendation for Fertilization

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: REPRODUCTIVE HEALTH

Description

Treats hypogonadism by stimulating the testes to produce more testosterone and sperm - in women, used to induce ovulation and fertilization

Specifications

Amount in Vial: 5000iu

BAC Water: 2ml

Amount per Unit: 25iu per unit

Injection Type: Subcutaneous

Recommended Dose: 500iu to 1000iu (20 to 40 units)

Frequency: Twice per week

Timing: Run 2 To 3 Times A Year Based On Needs and Based On Fertilization and Gonad Health

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 25iu per unit

Category: HEALING AND REPAIR

Description

Bpc-157 (body protection compound-157) is a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice. it is one of the most extensively studied healing peptides in preclinical research, with over 500 published studies from 1993 through 2025. its primary mechanisms include activation of the vegfr2 signaling pathway to promote angiogenesis (new blood vessel formation), erk1/2 signaling to enhance fibroblast activity and endothelial cell migration, upregulation of growth hormone receptor expression, and reduction of inflammatory cytokines. in animal models, bpc-157 has demonstrated protective and regenerative effects across muscle, tendon, ligament, bone, gut lining, heart, and nervous system tissue — earning the descriptors neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective. it is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys. as of 2025, three small pilot studies have been conducted in humans; larger controlled trials are pending. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous or im

Recommended Dose: 250mcg to 750mcg (10 to 30 units)

Frequency: Daily

Timing: Can Inject Locally Near Injury - Works in Synergy with TB-500

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: HEALING AND REPAIR

Description

Bpc-157 (body protection compound-157) is a synthetic pentadecapeptide of 15 amino acids, originally isolated from human gastric juice. it is one of the most extensively studied healing peptides in preclinical research, with over 500 published studies from 1993 through 2025. its primary mechanisms include activation of the vegfr2 signaling pathway to promote angiogenesis (new blood vessel formation), erk1/2 signaling to enhance fibroblast activity and endothelial cell migration, upregulation of growth hormone receptor expression, and reduction of inflammatory cytokines. in animal models, bpc-157 has demonstrated protective and regenerative effects across muscle, tendon, ligament, bone, gut lining, heart, and nervous system tissue — earning the descriptors neuroprotective, gastroprotective, cardioprotective, and musculoskeletal protective. it is metabolized in the liver with a half-life under 30 minutes and cleared by the kidneys. as of 2025, three small pilot studies have been conducted in humans; larger controlled trials are pending. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous or im

Recommended Dose: 250mcg to 750mcg (5 to 15 units)

Frequency: Daily

Timing: Can Inject Locally Near Injury - Works in Synergy with TB-500

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: HEALING AND REPAIR

Description

Tb-500 is a synthetic 7-amino acid peptide corresponding to amino acids 17–23 of thymosin beta-4 (tβ4), a naturally occurring 43-amino acid protein found at high concentrations in blood platelets and wound fluid. its central mechanism is g-actin sequestration — by binding to monomeric actin, tb-500 regulates cytoskeletal organization and enables rapid cell migration essential for tissue repair. different segments of the molecule address distinct functions: amino acids 1–4 drive anti-inflammatory and anti-fibrotic effects; amino acids 1–15 contribute to anti-apoptotic properties; amino acids 17–23 handle actin binding, angiogenesis, and dermal wound repair. in preclinical wound models, tb-500 administration increased re-epithelialization by 42% at day 4 and 61% at day 7 compared to controls, with thicker collagen fiber formation and reduced scarring. research has also explored its cardioprotective effects following cardiac injury, spinal cord neuroprotection, and corneal wound healing. a 2024 study confirmed activation of the wnt/β-catenin pathway, a primary driver of cell proliferation and tissue homeostasis. tb-500 is frequently studied alongside bpc-157 due to their complementary mechanisms. for research and educational purposes only. not fda-approved.

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2.5 to 5mg (50 to 100 units)

Frequency: Twice per week

Timing: Works in Synergy with BPC-157

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: HEALING AND REPAIR

Description

Tb-500 is a synthetic 7-amino acid peptide corresponding to amino acids 17–23 of thymosin beta-4 (tβ4), a naturally occurring 43-amino acid protein found at high concentrations in blood platelets and wound fluid. its central mechanism is g-actin sequestration — by binding to monomeric actin, tb-500 regulates cytoskeletal organization and enables rapid cell migration essential for tissue repair. different segments of the molecule address distinct functions: amino acids 1–4 drive anti-inflammatory and anti-fibrotic effects; amino acids 1–15 contribute to anti-apoptotic properties; amino acids 17–23 handle actin binding, angiogenesis, and dermal wound repair. in preclinical wound models, tb-500 administration increased re-epithelialization by 42% at day 4 and 61% at day 7 compared to controls, with thicker collagen fiber formation and reduced scarring. research has also explored its cardioprotective effects following cardiac injury, spinal cord neuroprotection, and corneal wound healing. a 2024 study confirmed activation of the wnt/β-catenin pathway, a primary driver of cell proliferation and tissue homeostasis. tb-500 is frequently studied alongside bpc-157 due to their complementary mechanisms. for research and educational purposes only. not fda-approved.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 2.5 to 5mg (25 to 50 units)

Frequency: Twice per week

Timing: Works in Synergy with BPC-157

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: HEALING AND REPAIR

Description

The wolverine blend combines bpc-157 and tb-500, two of the most studied healing peptides in preclinical research, targeting complementary tissue repair pathways in a single vial. bpc-157 works primarily through vegfr2 and erk1/2 signaling to promote angiogenesis, reduce inflammatory cytokines, and activate growth hormone receptors in tendon and muscle cells. tb-500 works through g-actin sequestration to enhance cell migration, reduce fibrosis, and accelerate re-epithelialization. together they address vascularization, cellular mobility, inflammation control, and structural tissue rebuilding simultaneously. researchers frequently combine these peptides because their mechanisms are additive rather than redundant — bpc-157 promotes new blood vessel formation while tb-500 drives the migration of repair cells into damaged tissue. the combination has shown promise in preclinical models for musculoskeletal injuries, gut healing, skin repair, and general tissue regeneration. for research and educational purposes only. not fda-approved.

Specifications

Amount in Vial: 20mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous or im

Recommended Dose: 500mcg to 1mg (10 to 20 units)

Frequency: 5-7 days per week

Timing: Do Not Inject Near Injury Site

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: GUT HEALING

Description

Bpc-157 in oral tablet form is specifically studied for gastrointestinal applications. unlike injectable bpc-157 which distributes systemically, oral administration concentrates the peptide in the gi tract — making it the preferred research route for gut lining repair, inflammatory bowel disease models, nsaid-induced gastric injury, and intestinal fistula healing. bpc-157 is notably chemically stable in gastric juice (it was originally isolated from gastric juice), allowing it to retain biological activity through the digestive tract. a 2025 systematic review published in the american journal of gastroenterology synthesized 36 studies (1993–2025) confirming bpc-157's cytoprotective and pro-healing effects across gi ulcer, anastomotic site repair, ibd models, and nsaid-induced injury — with the reviewers noting preclinical safety with no adverse organ system effects. oral bpc-157 is frequently studied for gastroprotection and leaky gut conditions. works synergistically with injectable tb-500 for systemic healing goals. for research and educational purposes only.

Specifications

Amount in Vial: 15mg (30 tablets)

BAC Water: n/a

Amount per Unit: 500mcg per tablet

Injection Type: Oral tablets

Recommended Dose: 500mcg to 1000mcg (1 to 2 tablets)

Frequency: Daily

Timing: As Needed Take with Meals

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 500mcg per tablet

Category: LONGEVITY

Description

Epithalon (epitalon) is a synthetic tetrapeptide (ala-glu-asp-gly) derived from epithalamin, a natural polypeptide produced by the pineal gland. its primary researched mechanism is activation of telomerase — the enzyme responsible for maintaining and extending the protective telomere caps at the ends of dna strands. telomeres shorten with each cell division; critically shortened telomeres trigger cellular senescence. epithalon is one of only a small number of compounds that has demonstrated telomerase activation in both in vitro and animal studies, positioning it as a significant subject of longevity research. secondary mechanisms include restoration of melatonin secretion via pineal gland normalization, antioxidant activity, and modulation of neuroendocrine function. in russian research spanning over 30 years, epithalon-treated animals showed increased lifespan, reduced tumor incidence, and improved physiological markers of aging. human studies remain limited. for research and educational purposes only.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 10mg (100 units)

Frequency: 20 bottle cycle (full bottle daily for 20 days)

Timing: 2x to 3x Annually

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: LONGEVITY

Description

Epithalon (epitalon) is a synthetic tetrapeptide (ala-glu-asp-gly) derived from epithalamin, a natural polypeptide produced by the pineal gland. its primary researched mechanism is activation of telomerase — the enzyme responsible for maintaining and extending the protective telomere caps at the ends of dna strands. telomeres shorten with each cell division; critically shortened telomeres trigger cellular senescence. epithalon is one of only a small number of compounds that has demonstrated telomerase activation in both in vitro and animal studies, positioning it as a significant subject of longevity research. secondary mechanisms include restoration of melatonin secretion via pineal gland normalization, antioxidant activity, and modulation of neuroendocrine function. in russian research spanning over 30 years, epithalon-treated animals showed increased lifespan, reduced tumor incidence, and improved physiological markers of aging. human studies remain limited. for research and educational purposes only.

Specifications

Amount in Vial: 50mg

BAC Water: 2ml

Amount per Unit: 0.25mg per unit

Injection Type: Subcutaneous

Recommended Dose: 10mg to 20mg (40 to 80 units)

Frequency: 4 bottle cycle over 10 to 20 days

Timing: 3x Annually

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.25mg per unit

Category: BRAIN + MOOD

Description

Innovative peptide for neuroprotection, cognitive support, and mood enhancement

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 300mcg to 1mg (3 to 10 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: LONGEVITY / MITOCHONDRIAL FUNCTION

Description

Nad+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every cell of the body. while technically a coenzyme rather than a peptide, injectable nad+ is included here because it participates in the same mitochondrial optimization protocols as peptides like mots-c and ss-31. nad+ is required for the electron transport chain and oxidative phosphorylation — without sufficient nad+, mitochondria cannot efficiently convert nutrients into atp. it also participates in over 500 enzymatic reactions and is the substrate required for sirtuin activation (sirt1–sirt7, the longevity-linked enzyme family), parp-mediated dna repair, and cd38-driven immune signaling. human studies confirm nad+ levels decline approximately 50% between ages 40 and 60. injectable nad+ bypasses the conversion steps required for oral precursors like nmn and nicotinamide riboside, delivering direct bioavailability. a 2024 meta-analysis in nature metabolism confirmed the safety and efficacy profile of direct nad+ supplementation approaches. for research and educational purposes only.

Specifications

Amount in Vial: 1000mg

BAC Water: 2ml

Amount per Unit: 5mg per unit

Injection Type: Intramuscular

Recommended Dose: 50mg to 150mg (10 to 30 units)

Frequency: 10 units daily or 20-30 units 2x per week

Timing: Single Dose Not To Exceed 250mg (50 Units)

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 5mg per unit

Category: BRAIN + MOOD

Description

Known as the love hormone - increases social bonding and emotional well being - helps with stress and anxiety

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg to 500mcg (5 to 10 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: BRAIN + MOOD

Description

Semax is a synthetic heptapeptide (met-glu-his-phe-pro-gly-pro) derived from acth (adrenocorticotropic hormone). it was developed in russia in the 1980s and has been approved there as a pharmaceutical for stroke, cognitive decline, and attention deficit disorders. its primary mechanism is stimulation of bdnf (brain-derived neurotrophic factor) release, a key protein for neuroplasticity — the brain's ability to form new neural connections, adapt to learning, and recover from injury. semax also increases cerebral blood flow, enhances dopamine and serotonin turnover, and modulates the expression of genes involved in neurogenesis. research has shown it may improve working memory, attention, and processing speed. its neuroprotective effects have been studied in ischemic stroke and traumatic brain injury models. semax is considered a nootropic and neuroprotective peptide with some of the strongest clinical backing in the brain peptide category due to its russian pharmaceutical history. for research and educational purposes only.

Specifications

Amount in Vial: 30mg

BAC Water: 3ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1000mcg (5 to 10 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: BRAIN + MOOD

Description

Anti-anxiety peptide - increases seratonin and dopamine signaling - enhanced learning and memory capacity

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg to 500mcg (5 to 10 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: BRAIN + MOOD

Description

Anti-anxiety peptide - increases seratonin and dopamine signaling - enhanced learning and memory capacity

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg to 500mcg (5 to 10 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: MUSCLE DEVELOPMENT

Description

Myostatin inhibitor - promotes increased muscle mass and strength - treats muscular atrophy - reduces cortisol

Specifications

Amount in Vial: 1mg

BAC Water: 1ml

Amount per Unit: 0.01mg per unit

Injection Type: Intramuscular

Recommended Dose: 200mcg (20 units)

Frequency: 4 bottle cycle over 20 days

Timing: 3x Annually

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: MITOCHONDRIAL FUNCTION

Description

Mots-c (mitochondrial orf of the 12s rrna type-c) is a 16-amino acid peptide uniquely encoded within the mitochondrial genome — one of the few known peptides not originating from nuclear dna. this gives it a direct and fundamental relationship with mitochondrial metabolic state. under metabolic stress, mots-c translocates from mitochondria to the cell nucleus, where it binds stress-response transcription factors nrf2 and atf1 to reprogram cellular metabolism. its primary signaling mechanism activates ampk (amp-activated protein kinase) — the same master metabolic switch triggered by intense exercise — which drives glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. in animal research: a 2021 nature communications study showed mots-c enhanced physical performance across age groups; a 2022 study showed a single dose improved running time by 12% and distance by 15%; a 2025 nature study demonstrated mots-c prevents pancreatic islet cell senescence, reducing diabetes progression. mots-c levels decline approximately 21% between ages 18–30 and ages 70–81. for research and educational purposes only.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 5mg - 10mg (50 units - 100 units)

Frequency: 1 injection every 5 days for 20 days

Timing: 3x Annually - If Type 2 Diabetic 1mg EOD

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: MITOCHONDRIAL FUNCTION

Description

Ss-31 (also known as elamipretide, bendavia, and forzinity) is a synthetic aromatic-cationic tetrapeptide engineered to concentrate at the inner mitochondrial membrane at levels approximately 1,000–5,000 times higher than surrounding cellular tissue. its mechanism is precise: ss-31 binds cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane that holds the electron transport chain machinery in place. as cardiolipin degrades with age and oxidative stress, the electron transport chain loosens, energy output drops, and reactive oxygen species (ros) production spikes. ss-31 stabilizes cardiolipin, tightening respiratory complexes i, iii, and iv, reducing ros production, and restoring efficient atp generation. in aged mice, a single ss-31 injection restored in vivo mitochondrial energetics to young-mouse levels within one hour. ss-31 (as elamipretide/forzinity) received fda accelerated approval in september 2025 for barth syndrome, a rare genetic disorder defined by defective cardiolipin remodeling — making it the first mitochondria-targeted therapeutic approved in the united states. for research purposes in non-barth applications, ss-31 remains investigational. for research and educational purposes only.

Specifications

Amount in Vial: 14mg

BAC Water: 1.2ml

Amount per Unit: 0.116mg per unit

Injection Type: Subcutaneous

Recommended Dose: 4.67mg (40 units)

Frequency: 7 bottle cycle 1x per day for 21 days 2 to 3x per year

Timing: Best To Use Before Running A MOTS-C Cycle

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.116mg per unit

Category: BRAIN + WEIGHTLOSS

Description

Sndri - enhance mood - suppress appetite - increased energy - cognitive function

Specifications

Amount in Vial: 15mg (30 tablets)

BAC Water: n/a

Amount per Unit: 500mcg per tablet

Injection Type: Oral tablets

Recommended Dose: 250mcg to 1000mcg (1/2 to 2 tablets)

Frequency: Daily

Timing: Fasted Upon Waking

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 500mcg per tablet

Category: BRAIN + WEIGHTLOSS

Description

Sndri - enhance mood - suppress appetite - increased energy - cognitive function

Specifications

Amount in Vial: 50mg (100 tablets)

BAC Water: n/a

Amount per Unit: 500mcg per tablet

Injection Type: Oral tablets

Recommended Dose: 250mcg to 1000mcg (1/2 to 2 tablets)

Frequency: Daily

Timing: Fasted Upon Waking

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 500mcg per tablet

Category: DELTA SLEEP/DETOX/WITHDRAWAL

Description

Resets circadian clock - supports nervous and hormonal system - support for alcohol and opioid withdrawal

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1mg (10 to 20 units)

Frequency: As needed before bed

Timing: Delta Sleep Inducing Peptide

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: LIBIDO/ED

Description

Signals central nervous system to enhance blood flow, arousal and libido in men and women

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg (10 units)

Frequency: As needed (2 hours before sexual activity)

Timing: Not To Exceed 20 Units (Consult With Doctor)

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: LIBIDO/ED

Description

Signals central nervous system to enhance blood flow, arousal and libido in men and women

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1mg (10 to 20 units)

Frequency: As needed (2 hours before sexual activity)

Timing: Not To Exceed 20 Units (Consult With Doctor)

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: MELANIN/LIBIDO

Description

Used for tanning (melanogenesis) - appetite suppression and enhanced sexual stimulus

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1mg (5 to 10 units)

Frequency: Every other day

Timing: Use 30 Minutes Before Tanning

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: MELANIN/LIBIDO

Description

Used for tanning (melanogenesis) - appetite suppression and enhanced sexual stimulus

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 1mg (5 to 10 units)

Frequency: Before tanning

Timing: Use 30 Minutes Before Tanning

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: BRAIN + REPAIR

Description

Brain function - stimulates neurogenesis - enhances cognition - mood regulation - memory and learning

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 2mg (5 to 20 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: IMMUNITY

Description

Antimicrobial, antiviral and antibiofilm - used as natural antibiotic - fights lung and gut infection

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 250mcg (10 units)

Frequency: While sick or to prevent illness

Timing: Stop Use When Feeling Healthy

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: IMMUNITY

Description

Antimicrobial, antiviral and antibiofilm - used as natural antibiotic - fights lung and gut infection

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 300mcg to 1mg (12 to 50 units)

Frequency: During illness

Timing: Stop Use When Feeling Healthy

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: HAIR/SKIN/COLLAGEN

Description

Ghk-cu (glycyl-l-histidyl-l-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine at concentrations that decline significantly with age — from approximately 200 ng/ml at age 20 to 80 ng/ml by age 60. its mechanisms are multi-directional: ghk-cu activates approximately 31% of human genes associated with tissue remodeling and repair, upregulates collagen and elastin synthesis, promotes antioxidant enzyme activity, modulates tgf-β to reduce fibrosis, and inhibits inflammatory cytokines. in skin research, it has demonstrated acceleration of wound healing, reduction of fine lines and wrinkles through collagen restoration, and improvement in skin laxity and firmness. in hair research, it promotes hair follicle size and has shown potential for androgenic alopecia. it also stimulates nerve outgrowth and has shown bone repair potential through increased osteoblast activity. for research and educational purposes only.

Specifications

Amount in Vial: 50mg

BAC Water: 2ml

Amount per Unit: 0.25mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (4 to 8 units)

Frequency: Daily

Timing: 30 Days On / 14 Days Off

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.25mg per unit

Category: HAIR/SKIN/COLLAGEN

Description

Ghk-cu (glycyl-l-histidyl-l-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine at concentrations that decline significantly with age — from approximately 200 ng/ml at age 20 to 80 ng/ml by age 60. its mechanisms are multi-directional: ghk-cu activates approximately 31% of human genes associated with tissue remodeling and repair, upregulates collagen and elastin synthesis, promotes antioxidant enzyme activity, modulates tgf-β to reduce fibrosis, and inhibits inflammatory cytokines. in skin research, it has demonstrated acceleration of wound healing, reduction of fine lines and wrinkles through collagen restoration, and improvement in skin laxity and firmness. in hair research, it promotes hair follicle size and has shown potential for androgenic alopecia. it also stimulates nerve outgrowth and has shown bone repair potential through increased osteoblast activity. for research and educational purposes only.

Specifications

Amount in Vial: 75mg

BAC Water: 2ml

Amount per Unit: 0.375mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (3 to 5 units)

Frequency: Daily

Timing: 30 Days On / 14 Days Off

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.375mg per unit

Category: ANTI-VIRAL, ANTI-MICROBIAL

Description

Reduces inflammatory cytokines - promotes wound healing - antimicrobial - helps with inflammatory bowel disease

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 200mcg to 500mcg (5 to 10 units)

Frequency: Based on injury

Timing: After Surgery, Preventative or Illness

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: ANTI INFLAMMATORY

Description

Modulates inflammatory pathways - promotes tissue repair - antioxidant - supports gut health

Specifications

Amount in Vial: 600mg

BAC Water: 2ml

Amount per Unit: 3mg per unit

Injection Type: Intramuscular

Recommended Dose: 45-90 mg (15 to 30 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 3mg per unit

Category: ANTI-VIRAL + ANTI CANCER + IMMUNITY

Description

Thymosin alpha-1 stimulates immune system - producing and activating t-cells, dendritic cells, and natural killer cells - eradicates bacteria, fungi and viruses

Specifications

Amount in Vial: 16.4mg

BAC Water: 1ml

Amount per Unit: 0.164mg per unit

Injection Type: Intramuscular

Recommended Dose: 3mg to 8mg (20 - 50 units)

Frequency: When sick 2x per week

Timing: Use When Sick 4x Per Year

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.164mg per unit

Category: ANTI-VIRAL + ANTI CANCER + IMMUNITY

Description

Thymosin alpha-1 stimulates immune system - producing and activating t-cells, dendritic cells, and natural killer cells - eradicates bacteria, fungi and viruses

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Intramuscular

Recommended Dose: 3mg to 8mg (30 - 80 units)

Frequency: When sick 2x per week

Timing: Use When Sick 4x Per Year

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: SKIN + TISSUE HEALING

Description

Enhance skin health - accelerate healing - support overall tissue regeneration

Specifications

Amount in Vial: 42mg

BAC Water: 3ml

Amount per Unit: 0.14mg per unit

Injection Type: Subcutaneous

Recommended Dose: 900mcg to 1800mcg (10 - 20 units)

Frequency: Daily

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.14mg per unit

Category: SKIN, HAIR AND COLLAGEN

Description

The klow blend is a four-peptide regenerative stack combining ghk-cu, kpv, bpc-157, and tb-500 — an evolution of the glow blend that adds kpv (a tripeptide fragment of alpha-msh) for targeted anti-inflammatory and mucosal barrier support. ghk-cu activates approximately 31% of human tissue remodeling genes and drives collagen and elastin synthesis. bpc-157 provides vegfr2-driven angiogenesis and erk1/2-mediated endothelial repair signaling. tb-500 contributes g-actin sequestration for rapid cell migration into repair sites and anti-fibrotic effects through its 1-4 amino acid segment. kpv adds a fourth mechanism: direct anti-inflammatory signaling via melanocortin receptor binding, reducing pro-inflammatory cytokines and supporting mucosal barrier integrity — making it particularly relevant for research combining skin regeneration with gut or systemic inflammatory pathway modulation. the 50mg ghk-cu concentration is the highest in any pre-formulated blend on this site, reflecting its foundational role in the stack. klow is most commonly compared to the glow blend — the key distinction is kpv's addition, which broadens the stack from a skin and tissue repair focus to include anti-inflammatory and gut-lining research applications simultaneously. for research and educational purposes only.

Specifications

Amount in Vial: 80mg total (ghk-cu 50mg / kpv 10mg / bpc-157 10mg / tb-500 10mg)

BAC Water: 3ml

Amount per Unit: approx 0.267mg per unit (26.7mg/ml total blend)

Injection Type: Subcutaneous

Recommended Dose: 1mg to 2mg (4 to 8 units)

Frequency: Daily

Timing: Morning or early afternoon subcutaneous injection. 30-day cycles with 14-day break. Store reconstituted vial refrigerated at 2-4 degrees C. Swirl gently to reconstitute — do not shake. Pairs with the individual GHK-Cu entry for extended cycles.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on approx 0.267mg per unit (26.7mg/ml total blend)

Category: MUSCLE DEVELOPMENT

Description

Mgf (mechano growth factor) is an alternative splice variant of the igf-1 gene, produced locally in skeletal muscle in response to mechanical stress and microtrauma such as resistance training. unlike systemic igf-1 which circulates throughout the body, mgf acts as a local first-responder — its mrna expression peaks within 2-3 hours after heavy resistance exercise and is blunted significantly with aging, which is why muscle recovery slows as we get older. its primary mechanism is satellite cell activation: mgf signals quiescent muscle stem cells to proliferate and begin the repair cascade, supplying more building blocks for subsequent tissue rebuilding. secondary mechanisms include activation of the mapk-erk1/2 pathway promoting osteoblast proliferation, cardioprotection via anti-apoptotic signaling, and chondrocyte protection against mechanical overload-induced cell death. native mgf has a half-life of only 5-7 minutes, limiting practical application. note: mgf is referenced in the 3x and 4x blend formulations on this site. this standalone entry covers the unmodified research peptide. for extended half-life, see peg-mgf. for research and educational purposes only.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Intramuscular

Recommended Dose: 100mcg to 200mcg (10 to 20 units)

Frequency: Daily (inject post-workout into target muscle)

Timing: Immediately post-training into the worked muscle group. Works synergistically with IGF1-LR3.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: MUSCLE DEVELOPMENT

Description

Peg-mgf (pegylated mechano growth factor) is a chemically modified version of mgf in which polyethylene glycol molecules are attached to the peptide structure through pegylation. this single modification solves mgf's primary limitation — extending the half-life from 5-7 minutes to several hours or days, allowing twice-weekly rather than daily dosing and enabling the peptide to remain in circulation long enough to exert meaningful systemic effects. peg-mgf works by activating muscle satellite cells — the stem-like progenitor cells responsible for muscle repair and hypertrophy — stimulating their proliferation and delaying premature differentiation, thereby expanding the pool of repair cells available after training-induced microtrauma. research has also demonstrated anti-apoptotic effects in cardiac myocytes, bone defect healing via osteoblast proliferation (1.4x greater effect than igf-1 in one study), and cartilage protection. because pegylation distributes the peptide systemically rather than locally, peg-mgf can be injected subcutaneously rather than requiring intramuscular injection into specific muscle groups. commonly studied alongside igf1-lr3 in a complementary protocol: peg-mgf post-workout for repair signaling, igf1-lr3 on rest days for growth. for research and educational purposes only.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous

Recommended Dose: 200mcg to 400mcg (20 to 40 units)

Frequency: 2 to 3 times per week

Timing: Post-workout administration. 5-6 week cycles. Stack with IGF1-LR3 on alternating days.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: BRAIN + MOOD

Description

Noopept (chemical name n-phenylacetyl-l-prolylglycine ethyl ester, also known as omberacetam or gvs-111) is a synthetic dipeptide developed in russia in 1996 as an orally bioavailable analogue of piracetam — approximately 1,000 times more potent per dose. it is one of the rare research peptides that works effectively via oral administration, crossing the blood-brain barrier within minutes. noopept is a prodrug metabolized in the body into its active form cycloprolylglycine, an endogenous dipeptide that acts as a positive modulator of ampa receptors and activates the bdnf/trkb signaling pathway. additional mechanisms include activation of the hypoxia-inducible factor 1 (hif-1) transcription pathway and upregulation of both bdnf and ngf expression. in russian clinical trials across 30+ years with over 1,000 subjects, noopept demonstrated 20-30% improvements on mmse cognitive scores versus placebo in patients with mild cognitive impairment. it also showed anxiolytic effects. standard protocol: 10mg twice daily for 1.5-3 month courses with at least 1 month break. oral administration — no reconstitution required. for research and educational purposes only.

Specifications

Amount in Vial: 30mg (30 tablets x 1mg)

BAC Water: n/a — oral tablets

Amount per Unit: 10mg per tablet

Injection Type: Oral tablets

Recommended Dose: 10mg to 30mg (1 to 3 tablets)

Frequency: Daily (take with or after meals)

Timing: Morning or split morning/midday. Last dose no later than mid-afternoon. Pair with Alpha-GPC 300mg or citicoline 250mg to prevent headaches. 1.5-3 month cycles with 1+ month break between.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 10mg per tablet

Category: BRAIN + REPAIR

Description

Pinealon (also known as the edr peptide, from its three amino acids glutamic acid, aspartic acid, arginine) is a synthetic tripeptide developed by professor vladimir khavinsky at the st. petersburg institute of bioregulation and gerontology, classified as a geroprotector — a compound designed to slow age-related biological decline. it is one of the smallest known neuroprotective peptides, with a molecular weight of 418.4 g/mol that allows it to cross the blood-brain barrier via the pept2 transporter system. pinealon's primary mechanism is epigenetic gene regulation: it directly influences the expression of genes involved in neurogenesis, memory formation, and circadian rhythm by entering cell nuclei and modulating transcription factor activity. it also increases irisin levels — a peptide linked to neuron proliferation and differentiation — and demonstrates antioxidant activity protecting neurons from oxidative and excitotoxic damage. research highlights include: 59.4% of patients recovering from traumatic brain injury showed measurable memory improvement when pinealon was added to standard rehabilitation; it is one of the active compounds in cortexin, a multi-peptide drug used clinically in several countries for tbi treatment. commonly stacked with epithalon for the complete khavinsky bioregulator protocol, and with pe-22-28 and selank for the calm and clarity blend. for research and educational purposes only.

Specifications

Amount in Vial: 20mg (20 tablets x 1mg)

BAC Water: n/a — oral tablets

Amount per Unit: 1mg per tablet

Injection Type: Oral tablets

Recommended Dose: 10mg to 20mg (10 to 20 tablets)

Frequency: Daily

Timing: Take daily in a 20-30 day cycle, 2-3 times annually. Stack with Epithalon for Khavinsky longevity protocol. Stack with PE-22-28 and Selank for the Calm and Clarity nootropic protocol.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 1mg per tablet

Category: MITOCHONDRIAL FUNCTION

Description

Humanin is a 21-amino acid mitochondrial-derived peptide first discovered in 2001 from the brain tissue of an alzheimer's disease patient — researchers noticed that specific brain cells were surviving in an otherwise degenerating environment and traced the protective signal to humanin, encoded within the 16s rrna region of the mitochondrial genome. along with mots-c and ss-31, humanin forms the core trio of mitochondrial-targeted research peptides. its primary mechanism is cytoprotection: humanin works by blocking pro-apoptotic proteins — particularly bax — at the mitochondrial membrane, preventing the release of cytochrome c that triggers programmed cell death. it also reduces beta-amyloid toxicity in neurons. in animal research, humanin has demonstrated protection of neurons against alzheimer's-associated apoptosis, prion disease, and forms of dementia; reduction of oxidative stress in retinal pigment epithelium; cytoprotective effects in heart, muscle, and blood vessel cells; and improved insulin sensitivity in aging models. humanin levels decline measurably with age and are lower in individuals with metabolic disease. unlike mots-c (which drives metabolic adaptation) and ss-31 (which repairs the inner membrane), humanin functions primarily as a cellular shield protecting existing cells from stress-induced death. the three peptides are mechanistically complementary and increasingly studied together in longevity protocols. for research and educational purposes only.

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: 500mcg to 2mg (10 to 40 units)

Frequency: Every other day or 3x per week

Timing: Morning SubQ injection. Benefits are long-term and cellular — expect 4-8 weeks before noticeable effects. Completes the mitochondrial trio alongside MOTS-c and SS-31.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: ANTI INFLAMMATORY

Description

Vip (vasoactive intestinal peptide) is a 28-amino acid neuropeptide and potent endogenous immune modulator found in the brain, gut, and throughout the nervous system. vip binds to vpac1 and vpac2 receptors on immune cells, reducing production of pro-inflammatory cytokines including il-6 and tnf-alpha by up to 40% in controlled research settings, without broadly suppressing the immune system — a critical distinction from corticosteroids. this selectivity makes it relevant in research for mast cell activation syndrome (mcas), chronic inflammatory response syndrome (cirs/mold illness), inflammatory bowel disease, pulmonary hypertension, copd, and rheumatoid arthritis. vip also synchronizes the suprachiasmatic nucleus (the brain's master clock) with light-dark cycles, making it relevant in circadian rhythm and sleep disorder research. administration note: vip has a plasma half-life of only 2-3 minutes when administered systemically. intranasal delivery routes bypass this issue by achieving direct cns transport via olfactory nerve at concentrations 10-15x higher than subcutaneous dosing. titration should be gradual — start low and increase over 2-3 weeks. vasodilatory flushing is common during initial administration and typically resolves as the body adapts. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous or intranasal

Recommended Dose: 50mcg to 200mcg (1 to 4 units)

Frequency: Daily or twice daily

Timing: Titrate up gradually from 50mcg. Intranasal preferred for CNS and circadian applications. SubQ for systemic anti-inflammatory use. Commonly used in MCAS stacks alongside LL-37, KPV, and TA-1.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: IMMUNITY

Description

Thymalin is a natural peptide bioregulator extracted from the thymus gland, developed by professor khavinsky's team at the st. petersburg institute of bioregulation and gerontology. the thymus gland is the primary organ responsible for t-cell development and immune education, but it undergoes progressive atrophy (involution) from early adulthood, shrinking significantly by age 40-50 and contributing to measurable immune decline associated with aging. thymalin's mechanism operates by restoring thymus function: it normalizes t-lymphocyte activity, regulates the balance between t-helper and t-suppressor cells, and stimulates both cellular and humoral immunity. in khavinsky's longitudinal research spanning 6-year follow-up periods, elderly patients treated with thymalin showed significantly reduced mortality rates and improved immune markers compared to control groups. it is classified as a geroprotector — a compound that slows the biological aging of immune function specifically. thymalin is commonly used in advanced longevity protocols alongside epithalon (for systemic anti-aging) and ta-1 (which more acutely activates t-cells for infectious challenges). where ta-1 is used acutely when sick, thymalin is used cyclically for long-term immune system restoration. for research and educational purposes only.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous or intramuscular

Recommended Dose: 5mg to 10mg (50 to 100 units)

Frequency: Daily for 10 days, 2-3x per year

Timing: 10-day cycles administered 2-3 times annually. Often paired with Epithalon cycles for the complete Khavinsky longevity protocol. Complements TA-1 for long-term immune restoration.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: BRAIN + REPAIR

Description

Dihexa (also known as pnb-0408) is a synthetic angiotensin iv-derived heptapeptide studied primarily for its synaptogenic properties — its ability to stimulate the formation of new synaptic connections in the brain. its researched mechanism involves activation of the hepatocyte growth factor (hgf) / c-met signaling pathway, which promotes new dendritic spine formation and synaptic plasticity. important evidence caveat: the foundational 2014 mechanism paper establishing the hgf/c-met pathway (benoist et al., journal of pharmacology and experimental therapeutics) was formally retracted by washington state university in april 2025 following findings of falsified and fabricated data. this significantly impacts the mechanistic evidence base. the compound remains heavily searched and widely discussed in the research community, and other preclinical work on synaptic enhancement continues, but users and researchers should approach dihexa with full awareness of this evidence gap. no approved human clinical trials exist. for research and educational purposes only. note: foundational mechanism paper retracted april 2025 — evidence base is currently limited. consult a qualified healthcare professional.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous or oral

Recommended Dose: 1mg to 2mg (10 to 20 units)

Frequency: Daily or every other day

Timing: Often dosed orally in community protocols. Cycle length 4-8 weeks. Stack with Semax or BDNF for complementary neuroprotective mechanisms.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: BRAIN + MOOD

Description

The calm and clarity blend combines three complementary nootropic peptides — pe-22-28, pinealon, and selank — each targeting a distinct cognitive pathway with no mechanism overlap. pe-22-28 works on neuroprotection and bdnf-linked mood stabilization. pinealon (edr peptide) targets epigenetic gene regulation of neurogenesis and memory consolidation, crossing the blood-brain barrier to influence transcription directly. selank modulates gabaergic signaling and serotonin-dopamine balance for acute anxiety reduction and calm focus. together they address structural cognitive support (pinealon), acute anxiolytic and focus enhancement (selank), and mood-stabilizing neuroprotection (pe-22-28) — three mechanisms that work without redundancy. this is one of the most widely referenced pre-mixed nootropic stacks in the peptide research community. all three components are available individually on this site.

Specifications

Amount in Vial: 20mg total

BAC Water: 2ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 300mcg to 1mg (3 to 10 units)

Frequency: Daily

Timing: Morning or early afternoon. Cycle 20-30 days on with 2-week break.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: LONGEVITY / MITOCHONDRIAL FUNCTION

Description

The mito stack combines the three most researched mitochondrial-targeted compounds available, each addressing a different failure point in the mitochondrial energy system. ss-31 (elamipretide) repairs the inner mitochondrial membrane by binding and stabilizing cardiolipin — the phospholipid that holds the electron transport chain in place. when cardiolipin degrades with age, electron flow becomes inefficient and reactive oxygen species production spikes. ss-31 fixes this structural problem first. mots-c then acts as the metabolic reprogramming signal — a mitochondria-encoded peptide that activates ampk, driving mitochondrial biogenesis, glucose uptake, and fat oxidation. finally, nad+ supplies the essential coenzyme substrate that every mitochondrial energy process depends on, restoring the declining nad+ pool that drops approximately 50% between ages 40 and 60. the protocol sequence matters: ss-31 first to repair membrane integrity, mots-c added to build new mitochondrial capacity on a repaired foundation, nad+ supporting both throughout. ss-31 received fda accelerated approval as elamipretide/forzinity for barth syndrome in september 2025 — the first mitochondria-targeted therapeutic approved in the us. for research and educational purposes only.

Specifications

Amount in Vial: sold as 3-part cycle protocol

BAC Water: see individual peptide entries

Amount per Unit: see individual entries

Injection Type: Subcutaneous (ss-31, mots-c) / intramuscular (nad+)

Recommended Dose: see individual peptide entries for precise dosing

Frequency: 12-week protocol — ss-31 weeks 1-3, mots-c weeks 4-8, nad+ throughout

Timing: Phase 1: SS-31 daily for 21 days to restore membrane integrity. Phase 2: Add MOTS-c every 5 days for 20 days. NAD+: 50-150mg IM, 10 units daily or 2x/week throughout. 2-3 cycles per year.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on see individual entries

Category: LONGEVITY

Description

Foxo4-dri (foxo4 d-retro-inverso) is the most researched peptide senolytic — a compound that selectively induces apoptosis in senescent cells by blocking the foxo4-p53 pro-survival interaction. senescent cells are cells that have permanently stopped dividing but remain metabolically active, secreting pro-inflammatory sasp (senescence-associated secretory phenotype) compounds including il-6, tnf-alpha, and matrix metalloproteinases that accelerate aging in surrounding tissue. foxo4-dri disrupts the foxo4-p53 complex specifically in senescent cells (which upregulate foxo4 to resist apoptosis), restoring p53's pro-apoptotic function and triggering selective senescent cell death while leaving healthy cells intact. the landmark 2017 nature paper by baar et al. demonstrated measurable rejuvenation phenotypes in naturally aged mice following treatment. a 2025 nature communications study confirmed the mechanism at atomic resolution. the d-retro-inverso modification uses d-amino acids in reversed sequence, creating resistance to proteolytic degradation and extending half-life. foxo4-dri is studied in longevity protocols alongside epithalon, and senolytics research often pairs it with navitoclax or dasatinib for complementary bcl-2 pathway targeting. for research and educational purposes only.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 100mcg to 500mcg (4 to 20 units)

Frequency: 3 times per week for 3 weeks (1-2x annually)

Timing: Every other day, 3x/week for 3 weeks per cycle. 1-2 cycles per year. Allow 4-6 weeks post-cycle for cellular clearance effects. Benefits are cumulative and emerge over weeks to months. Commonly studied alongside Epithalon for the longevity-focused protocol. Store at -20C before reconstitution; use within 30 days once reconstituted.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: IMMUNITY

Description

Ara-290 (cibinetide) is a non-hematopoietic erythropoietin (epo) analogue engineered to remove epo's erythropoietic (red blood cell-stimulating) activity while preserving its tissue-protective and anti-inflammatory signaling through the innate repair receptor (irr). the irr is a heterodimer of the epo receptor (epor) and the common beta receptor (cd131) expressed on immune cells, neurons, and injured tissues — distinct from the classical epor homodimer that drives red blood cell production. ara-290 binding to the irr activates anti-inflammatory pathways including inhibition of nf-kb, reduction of pro-inflammatory cytokines (il-1beta, tnf-alpha, il-6), and stimulation of tissue repair signaling without thrombotic or erythropoietic side effects. fda fast-track designation was granted for autoimmune small fiber neuropathy (sfn) — a painful peripheral nerve condition — following phase 2b clinical trials demonstrating improved corneal nerve fiber density (a proxy for sfn severity) and symptom reduction. ara-290 is studied in the mcas protocol stack alongside vip (mast cell stabilization), kpv (mucosal anti-inflammation), and ta-1 (t-regulatory normalization). for research and educational purposes only.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous

Recommended Dose: 100mcg to 400mcg (10 to 40 units)

Frequency: Daily or every other day

Timing: Morning SubQ injection. 12-week cycles used in Phase 2b clinical trials. Stack with VIP, KPV, and TA-1 for the full MCAS protocol. Titrate up gradually from 100mcg. Store refrigerated after reconstitution; use within 30 days.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: GUT HEALING

Description

Larazotide acetate (at-1001) is a synthetic 8-amino acid peptide derived from vibrio cholerae zona occludens toxin (zot) that acts as a tight junction regulator — the most specific peptide tool available for intestinal barrier research. larazotide's mechanism is precise: it blocks the action of zonulin — the endogenous protein that triggers tight junction disassembly and increases intestinal permeability ('leaky gut') — by competitively inhibiting zonulin receptor binding on intestinal epithelial cells. unlike compounds that repair existing tissue damage, larazotide acts at the structural barrier level, preventing the paracellular leakage of antigens, pathogens, and toxins that drives gut-systemic inflammation. phase 2 clinical trials demonstrated significant reduction in intestinal permeability markers, anti-gliadin antibody levels, and gastrointestinal symptoms in celiac disease patients. separate trials in non-celiac ibd populations showed favorable safety and symptom improvement. larazotide is the structural component of the gut healing stack, where it works alongside kpv (melanocortin receptor-mediated mucosal anti-inflammation) and bpc-157 oral tablets (vegfr2-driven tissue repair) to address all three foundational layers of gut dysfunction simultaneously. all-oral administration targets the intestinal lining directly. for research and educational purposes only.

Specifications

Amount in Vial: 10mg (10 tablets x 1mg)

BAC Water: n/a — oral tablets

Amount per Unit: 1mg per tablet

Injection Type: Oral tablets

Recommended Dose: 0.25mg to 1mg (0.25 to 1 tablet per dose, three times daily)

Frequency: Three times daily, 30 minutes before meals

Timing: Take 30 minutes before each meal for maximum tight junction protection during food antigen exposure. Phase 2 celiac trials used 0.25mg, 1mg, or 2mg TID — current community protocols use 0.5-1mg TID. Part of the Gut Healing Stack with KPV and BPC-157 Oral Tablets. Can be run continuously or in 4-6 week cycles.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 1mg per tablet

Category: BRAIN + REPAIR

Description

P21 is a tetrapeptide (davp sequence) derived from the c-terminal region of cntf (ciliary neurotrophic factor) that stimulates hippocampal neurogenesis — the formation of new neurons in the brain's primary memory and spatial navigation center — without triggering cntf's adverse off-target effects including severe weight loss, inflammation, cachexia, and broad systemic toxicity that limit cntf's research utility. p21 was developed specifically to isolate cntf's neuroprotective and neurogenic activity in a small, bbb-penetrant peptide. its mechanisms include stimulation of bdnf (brain-derived neurotrophic factor) expression, reduction of tau phosphorylation (a hallmark of alzheimer's pathology and tauopathies), inhibition of cntf's negative feedback through socs proteins, and direct promotion of neural progenitor cell differentiation in the hippocampal dentate gyrus. in alzheimer's disease animal models, p21 increased brain volume and hippocampal cell counts. in a head-to-head preclinical comparison, p21 outperformed cerebrolysin (a clinically used multi-peptide brain treatment mixture) on neurogenesis and cognitive outcome measures. p21 crosses the blood-brain barrier following subcutaneous injection. classified in the brain + repair category for its structural regenerative mechanism rather than acute mood or anxiolytic modulation. complementary to semax (bdnf pathway upregulation), dihexa (synaptogenesis via hgf/c-met), and pe-22-28 (mood-stabilizing neuroprotection). for research and educational purposes only.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 100mcg to 200mcg (4 to 8 units)

Frequency: Daily

Timing: Morning SubQ injection. 20-30 day cycles with 1-2 week break. Blood-brain barrier penetrant — SubQ dosing achieves CNS delivery. Stack with Dihexa or Semax for comprehensive neurogenesis support. Expect 4-6 weeks before cognitive effects become apparent. Store at -20C before reconstitution; use within 30 days once reconstituted.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: MITOCHONDRIAL FUNCTION

Description

Shlp2 (small humanin-like peptide 2) is a 20-amino acid mitochondria-encoded peptide discovered in 2016 by researchers at the usc davis school of gerontology, encoded within the 12s ribosomal rna region of the mitochondrial genome — the same genomic locus that encodes humanin. shlp2 belongs to the shlp family (shlp1-6), all sharing structural homology with humanin but exerting distinct biological profiles. shlp2's primary mechanisms include cytoprotection against oxidative stress-induced cell death (analogous to humanin's protective effect), regulation of anabolic hormone signaling — it modulates igf-1 responsiveness and improves insulin sensitivity in aging models — and mitochondrial quality maintenance. shlp2 levels decline measurably with age, paralleling humanin's age-related decline and suggesting a coordinated mitochondrial aging response. unlike mots-c (which activates ampk for metabolic reprogramming) and ss-31 (which repairs membrane structural integrity), shlp2 functions primarily in cellular protection and anabolic signaling preservation — a distinct fourth role in the mitochondrial-derived peptide family. shlp2 completes the mitochondrial research protocol alongside humanin (cytoprotection/anti-apoptosis), mots-c (metabolic reprogramming), and ss-31 (membrane repair). research on shlp2 is earlier-stage than humanin and mots-c but rapidly expanding. for research and educational purposes only.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous

Recommended Dose: 50mcg to 200mcg (5 to 20 units)

Frequency: Every other day or 3x per week

Timing: Morning SubQ injection. 8-12 week research cycles. Completes the mitochondrial-derived peptide family alongside Humanin, MOTS-c, and SS-31. Benefits are long-term and cellular — expect 4-8 weeks before effects are measurable. Store at -20C before reconstitution; use within 30 days.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: MITOCHONDRIAL FUNCTION

Description

Shlp6 (small humanin-like peptide 6) is a 20-amino acid mitochondria-encoded peptide from the 12s rrna gene region, identified alongside shlp2 and the other shlp family members in the 2016 usc discovery. shlp6 is notable for a unique dual biological profile that distinguishes it from all other mitochondrial-derived peptides: it is cytoprotective in normal, healthy cells — protecting them from oxidative damage and stress-induced death — while demonstrating pro-apoptotic activity in cancer cell lines, selectively triggering programmed death in transformed cells. this cancer-selective pro-apoptotic property is not shared by humanin, mots-c, ss-31, or shlp2, and makes shlp6 the subject of distinct oncological and cytoprotection research tracks. the mechanism of shlp6's cancer selectivity is under active investigation — leading hypotheses involve differential expression of shlp6 receptors on cancer cells versus normal cells and distinct activation of intrinsic apoptosis pathways in transformed versus untransformed cells. like other shlps, shlp6 levels decline with age. its complete biological role in the mitochondrial aging axis is still being characterized. for research and educational purposes only. note: pro-apoptotic activity in cancer cells means this peptide has uniquely specialized research applications compared to the other mdps.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous

Recommended Dose: 50mcg to 150mcg (5 to 15 units)

Frequency: Every other day or 3x per week

Timing: Morning SubQ injection alongside SHLP2 if running full MDP protocol. 8-12 week research cycles. Unique pro-apoptotic profile in cancer cell lines distinguishes this from other MDPs. Research note: distinct oncological research applications beyond the standard longevity/mitochondrial protocol. Store at -20C before reconstitution.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: REPRODUCTIVE HEALTH

Description

Triptorelin is a long-acting synthetic gnrh (gonadotropin-releasing hormone) agonist decapeptide with approximately 100 times the receptor binding potency of native gnrh. triptorelin's primary research application in the peptide community is hpg (hypothalamic-pituitary-gonadal) axis restart after suppression from exogenous testosterone (trt) or anabolic androgen use — a protocol where a single low dose (0.1mg) triggers a powerful initial lh and fsh flare response by massively stimulating pituitary gnrh receptors before the agonist-induced downregulation of those receptors occurs. this flare effect is exploited in restart protocols because an hpg-suppressed axis responds to the initial gnrh surge with a compensatory lh spike that stimulates leydig cell testosterone production. in sustained use (as in prostate cancer treatment), continuous gnrh agonism causes receptor downregulation and hormonal castration — the opposite of the restart effect. the restart protocol is a precise single-dose application. approved medically as trelstar (usa) and decapeptyl (eu) for prostate cancer, endometriosis, and precocious puberty in long-acting depot formulations. the restart application uses a very small single subcutaneous dose, not a depot preparation. post-trt restart: wait 4-6 weeks after last testosterone dose before administration. monitor lh, fsh, and total testosterone at 2 and 4 weeks post-dose to confirm axis recovery. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 2mg

BAC Water: 2ml

Amount per Unit: 0.01mg per unit

Injection Type: Subcutaneous

Recommended Dose: 0.1mg (10 units) — single dose for hpg restart

Frequency: Single dose protocol — not for repeated use

Timing: Single 0.1mg (10 unit) dose for HPG axis restart. Administer 4-6 weeks after last exogenous androgen dose. Monitor LH, FSH, total testosterone at 2 and 4 weeks post-administration. Not for chronic or repeated dosing — sustained agonism causes receptor downregulation and hormonal suppression rather than stimulation. The full 2mg vial provides 20 single restart doses — store remaining reconstituted solution at 4C and use within 30 days.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.01mg per unit

Category: IMMUNITY

Description

Thymulin (also known as facteur thymique serique, fts, or serum thymic factor) is a naturally occurring thymic nonapeptide hormone that requires zinc chelation for biological activity — inactive zinc-free thymulin circulates in serum and becomes active only when zinc binds to complete the bioactive complex. thymulin was first isolated from thymic extracts by bach and dardenne in 1972. its primary mechanism is the induction and differentiation of t-lymphocytes: thymulin binds specific receptors on t-cell precursors (thymocytes) and drives their maturation into functional t-helper (cd4+) and t-cytotoxic (cd8+) cells with restored functional capacity. secondary mechanisms include normalization of nk cell activity, regulation of thyroid-thymus cross-signaling, and anti-inflammatory cytokine modulation. thymulin levels are measurably low in individuals with zinc deficiency, explaining the immune suppression associated with zinc deficiency states. thymulin is distinct from thymalin (a full thymic extract bioregulator from khavinsky's group containing multiple peptide fractions) and from ta-1 (thymosin alpha-1, which activates t-cells more acutely). thymulin addresses thymic t-cell education specifically — the earliest step in adaptive immune competence — while thymalin provides broader thymic bioregulation. zinc sufficiency is required for activity; supplement with 30-50mg zinc daily during thymulin research cycles. for research and educational purposes only.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 10mcg to 100mcg (0.4 to 4 units)

Frequency: Daily for 5-10 days, 2-3x per year

Timing: Short cycle protocol: 5-10 days daily dosing, 2-3 times annually. Zinc supplementation required for biological activity — take 30-50mg zinc daily throughout the cycle. Distinct from Thymalin (full thymic extract) and TA-1 (acute T-cell activator). Thymulin targets T-cell differentiation specifically. Can be stacked with Thymalin for the complete Khavinsky thymic restoration protocol.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: BRAIN + MOOD

Description

Vasopressin (also called arginine vasopressin, avp, or antidiuretic hormone, adh) is a 9-amino acid neuropeptide produced in the supraoptic and paraventricular nuclei of the hypothalamus and secreted by the posterior pituitary gland. vasopressin serves distinct peripheral and central roles. peripherally, it regulates water reabsorption in the renal collecting ducts (antidiuretic effect) and causes vasoconstriction through v1a receptors in vascular smooth muscle. centrally, v1a and v1b receptor signaling in limbic and social brain regions — including the amygdala, lateral septum, and bed nucleus of the stria terminalis — influences social memory, pair bonding, trust, and prosocial behavior through mechanisms complementary to but distinct from oxytocin. key differences from oxytocin: vasopressin has greater effects on social aggression and territorial behavior (particularly in males), stronger effects on social memory formation, and different receptor distribution (denser v1a expression in reward pathways). v1b receptors in the anterior pituitary regulate acth release and stress axis modulation. in research applications, intranasal vasopressin is studied for social cognition in autism spectrum disorder (asd), trust enhancement, and social behavior modulation. vasopressin and oxytocin differ by only 2 amino acids (positions 3 and 8) but bind distinct receptor subtypes with substantially different downstream signaling. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: 2mg

BAC Water: 4ml

Amount per Unit: 0.005mg per unit

Injection Type: Intranasal or subcutaneous

Recommended Dose: 2mcg to 20mcg (0.4 to 4 units)

Frequency: As needed or daily (intranasal); daily (subcutaneous)

Timing: Intranasal preferred for CNS social behavior and memory applications — onset within 15-30 minutes. SubQ for peripheral research applications. Titrate gradually — begin at lowest dose (2mcg) and increase cautiously. Compare with oxytocin for social neuropeptide research — similar structure, distinct receptor profiles and behavioral effects. Effects are rapid and relatively short-lived (1-3 hours); time dosing to research windows.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.005mg per unit

Category: BRAIN + REPAIR

Description

Cortagen is a synthetic tripeptide bioregulator (edr: glutamic acid-aspartic acid-arginine) developed by professor vladimir khavinsky at the st. petersburg institute of bioregulation and gerontology, specifically targeting neuroprotection and functional restoration of cerebral cortex neurons. cortagen is structurally related to pinealon (also an edr-sequence peptide), but the two are formulated for distinct brain regions: pinealon targets hippocampal memory consolidation and pineal gland neurogenesis, while cortagen targets the cerebral cortex — higher cognitive function, executive processing, and cortical neuroprotection against age-related decline. cortagen's mechanism operates through the same epigenetic gene regulation pathway as pinealon: it penetrates cell nuclei and modulates transcription factor activity, influencing the expression of genes governing neuronal survival, neurotrophin production, and anti-apoptotic signaling in cortical tissue. classified as a geroprotector — a compound designed to slow age-related biological decline in cortical function. cortagen is part of the expanded khavinsky brain bioregulator protocol: pinealon for hippocampal-pineal axis (memory + melatonin restoration), cortagen for cortical neuroprotection, epithalon for pineal telomere-telomerase axis, and thymalin for immune aging. available as oral tablets for direct gut-brain delivery without injection. for research and educational purposes only.

Specifications

Amount in Vial: 10mg (10 tablets x 1mg)

BAC Water: n/a — oral tablets

Amount per Unit: 1mg per tablet

Injection Type: Oral tablets

Recommended Dose: 5mg to 10mg (5 to 10 tablets)

Frequency: Daily

Timing: Take daily in 20-30 day cycles, 2-3 times annually. Stack with Pinealon for the complete Khavinsky hippocampal-cortical protocol. Stack with Epithalon for the full Khavinsky longevity bioregulator series. Pairs with PE-22-28 and Semax for comprehensive brain support research. Note: Cortagen (cortical neuroprotection) and Pinealon (hippocampal-pineal) are complementary, not redundant — each targets a distinct brain region.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 1mg per tablet

Category: IMMUNITY

Description

Bt-11 is a gut-restricted, orally bioavailable small molecule peptide ligand developed by landos biopharma that selectively activates the lancl2 (lanc like protein 2) signaling pathway in intestinal immune cells. bt-11 is specifically engineered for gut lumen restriction — it does not cross the intestinal epithelium and achieves no meaningful systemic absorption, making it a uniquely targeted gut immune modulator that avoids systemic side effects. lancl2 is a mammalian homologue of bacterial lanc enzymes that functions as a receptor for abscisic acid (aba), a plant hormone also produced in human immune cells. lancl2 activation drives immunoregulatory effects including increased il-10 production, reduced il-17 and tnf-alpha secretion, and promotion of t-regulatory cell function in the gut-associated lymphoid tissue (galt) — recalibrating the hyperactive mucosal immune responses driving ibd and crohn's disease. phase 2 clinical trials for crohn's disease demonstrated favorable safety, reduced fecal calprotectin (an inflammation marker), and symptom improvement. bt-11 addresses mucosal immune dysregulation while larazotide addresses tight junction structure — the two compounds are mechanistically complementary in gut healing research. pairs well with the full gut healing stack (larazotide + kpv + bpc-157 oral) for multi-mechanism gut barrier restoration. for research and educational purposes only.

Specifications

Amount in Vial: 10mg (10 tablets x 1mg)

BAC Water: n/a — oral tablets

Amount per Unit: 1mg per tablet

Injection Type: Oral tablets

Recommended Dose: 1mg to 5mg (1 to 5 tablets)

Frequency: Daily with meals

Timing: Take with food for maximum gut lumen exposure and tolerability. Designed for gut-restricted delivery — engineered not to cross the epithelium. Phase 2 trials used 500mg and 1000mg doses (note: these clinical doses refer to the full capsule formulation including excipients; the active peptide component is the key variable). Pairs with Larazotide (tight junction repair) and KPV (mucosal anti-inflammation) for the gut healing protocol. Can be run continuously or in 4-6 week cycles.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 1mg per tablet

Category: GUT HEALING

Description

The gut healing stack combines three oral gut-targeted peptides into the most comprehensive all-oral gut research protocol available — each addressing a distinct mechanism of intestinal dysfunction with no mechanistic overlap. bpc-157 oral tablets provide tissue healing at the intestinal epithelium through vegfr2-driven angiogenesis and erk1/2-mediated endothelial repair signaling, accelerating recovery of physically damaged gut lining. kpv (a tripeptide fragment of alpha-msh) addresses mucosal inflammation through melanocortin receptor (mc1r, mc3r) binding, reducing pro-inflammatory cytokines (il-6, tnf-alpha, il-1beta) and supporting mucosal barrier cell migration — particularly relevant for ibd, colitis, and intestinal inflammation. larazotide (at-1001) specifically targets tight junction structural integrity — the gatekeeping protein network of the gut barrier — by blocking zonulin-mediated junction disassembly and preventing increased intestinal permeability. together, the three peptides address healing (bpc-157), inflammation (kpv), and barrier structure (larazotide) — the three foundational layers of gut dysfunction — through mechanistically non-redundant pathways. the all-oral administration route is the defining feature of this stack: it enables direct targeting of the intestinal lining without systemic distribution, making it the only major research stack on this site that requires no injection. larazotide is taken 30 minutes before meals; bpc-157 oral and kpv are taken with meals. for research and educational purposes only.

Specifications

Amount in Vial: 30mg total (3-part oral protocol)

BAC Water: n/a — all oral tablets

Amount per Unit: see individual entries

Injection Type: Oral tablets only

Recommended Dose: see individual peptide entries for precise dosing

Frequency: Daily — larazotide 3x daily before meals; bpc-157 and kpv with meals

Timing: Larazotide: 30 min before each of 3 meals. BPC-157 Oral and KPV: taken with meals. All-oral stack for gut-specific targeting without systemic bypass. Can be run continuously or in 30-day cycles. See individual peptide entries (BPC-157 Oral Tablets, KPV, Larazotide) for specific dosing per component.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on see individual entries

Category: LONGEVITY

Description

The longevity master stack is the most comprehensive anti-aging research protocol available on this site — four peptides targeting four distinct biological aging mechanisms simultaneously, with no mechanistic overlap between any of the four components. epithalon (tetrapeptide bioregulator, khavinsky lab) targets the pineal-telomere axis: it stimulates telomerase activity to lengthen critically short telomeres in aging cells, restores declining melatonin secretion from the involuting pineal gland, and regulates the broader neuroendocrine aging axis. thymalin (thymic bioregulator, khavinsky lab) addresses immune aging — the progressive atrophy of thymic function that drives t-cell exhaustion and immunosenescence from early adulthood. in khavinsky's landmark 6-year longitudinal study, elderly patients receiving combined epithalon and thymalin treatment showed significantly reduced mortality compared to controls. mots-c (mitochondrial-derived peptide, usc) drives metabolic reprogramming via ampk activation, restoring mitochondrial biogenesis and metabolic flexibility that decline with age. ss-31 (elamipretide, approved september 2025 as forzinity for barth syndrome) repairs the inner mitochondrial membrane by stabilizing cardiolipin — the phospholipid that anchors the electron transport chain — reversing the structural degradation that reduces energy output in aging mitochondria. each of the four compounds operates through a completely independent mechanism (epigenetic/telomere, immune, mitochondrial biogenesis, mitochondrial membrane) — they work additively rather than redundantly, maximizing the research protocol's coverage of the biology of aging. for research and educational purposes only.

Specifications

Amount in Vial: sold as 4-part longevity protocol

BAC Water: see individual peptide entries

Amount per Unit: see individual entries

Injection Type: Subcutaneous (all four components)

Recommended Dose: see individual peptide entries for precise dosing

Frequency: Epithalon daily 10 days; thymalin daily 10 days; mots-c 3x per week; ss-31 daily

Timing: Phase 1 (Days 1-10): Epithalon + Thymalin together daily (Khavinsky dual bioregulator protocol — these two are always run simultaneously). Phase 2 (Weeks 3-10): Add MOTS-c every 5 days SubQ. SS-31: daily SubQ 100-300mcg throughout all phases. Complete 2 full cycles per year. See individual entries for precise reconstitution and dosing of each component.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on see individual entries

Category: IMMUNITY

Description

The mcas protocol stack combines four immune-modulating peptides that address mast cell activation syndrome (mcas) and cirs (chronic inflammatory response syndrome) through four distinct, non-overlapping mechanisms. vip (vasoactive intestinal peptide) acts as the primary mast cell degranulation suppressor — binding vpac1/vpac2 receptors on mast cells and immune cells to reduce histamine release, reduce pro-inflammatory cytokines (il-6, tnf-alpha) by up to 40%, and modulate the mast cell response without broadly suppressing immune function. vip also synchronizes the suprachiasmatic nucleus for circadian rhythm regulation relevant to immune cycling. ara-290 (cibinetide) adds neuroprotective and tissue-repair signaling via the innate repair receptor (irr) — particularly relevant for the small fiber neuropathy (sfn) that is commonly comorbid with mcas, addressing the neurological component of mast cell-driven tissue damage. kpv (melanocortin tripeptide from alpha-msh) provides targeted mucosal anti-inflammatory signaling via mc1r and mc3r, reducing gut and skin inflammation driven by mast cell degranulation products. ta-1 (thymosin alpha-1) normalizes t-regulatory (treg) cell populations — restoring the immune calibration that prevents the hyperactive immune responses driving mcas chronicity. the four mechanisms collectively address mast cell activity (vip), neuroprotection (ara-290), mucosal anti-inflammation (kpv), and t-regulatory normalization (ta-1) — the most complete peptide-based mcas research protocol available. for research and educational purposes only. consult a qualified healthcare professional.

Specifications

Amount in Vial: sold as 4-part immune protocol

BAC Water: see individual peptide entries

Amount per Unit: see individual entries

Injection Type: Intranasal (vip) + subcutaneous (ara-290, kpv, ta-1)

Recommended Dose: see individual peptide entries for precise dosing

Frequency: Vip daily intranasal; ara-290 daily subcutaneous; kpv daily subcutaneous; ta-1 2x per week subcutaneous

Timing: Week 1: Begin VIP alone, titrating from 50mcg intranasal twice daily — establish mast cell stabilization baseline before adding other components. Week 2+: Add ARA-290 100-200mcg SubQ morning and KPV 200-500mcg SubQ daily. Week 3+: Add TA-1 1.5mg SubQ twice weekly. This staged introduction allows identification of individual compound tolerability. See individual entries (VIP, KPV, TA-1) for full reconstitution and dosing. Ongoing monitoring of symptom load recommended throughout.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on see individual entries

Category: WEIGHT MANAGEMENT

Description

Retatrutide (ly3437943) -- widely called "reta", "ret", or "glp-3" in the research and biohacking communities -- is a synthetic 39-amino acid triple receptor agonist developed by eli lilly that simultaneously activates glp-1 (glucagon-like peptide-1), gip (glucose-dependent insulinotropic polypeptide), and glucagon receptors. it is the most potent weight management compound in phase 3 clinical research as of 2026. phase 2 data showed 24.2% mean weight loss at 48 weeks with no plateau. triumph-4 phase 3 data reported 26-29% mean weight loss at 48-68 weeks -- the highest ever recorded in a controlled pharmaceutical obesity trial -- with participants still actively losing weight at study end. the glucagon receptor component uniquely adds resting metabolic rate increase and hepatic fat oxidation on top of the appetite suppression driven by glp-1/gip agonism, producing additive weight loss that mono- and dual agonists cannot match. masld (metabolic dysfunction-associated steatotic liver disease) normalization occurred in approximately 93% of participants in sub-studies, with more than 80% reduction in liver fat content. lean mass is largely preserved through gip receptor co-activation. gastrointestinal tolerability is comparable to tirzepatide and better than semaglutide at equivalent weight-loss-producing doses -- partly because gip co-agonism buffers the gi side effects of glp-1 agonism. also known as glp-3 or glp-3 r in some research supply catalogs. as of may 2026, retatrutide has not received fda approval and remains a research compound. for research and educational purposes only. independent purity testing warning (june 2026): 37 of 37 independently tested grey-market retatrutide samples received failing purity grades per chainalysis reporting. source only from vendors providing current, batch-specific hplc certificates of analysis.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 0.5mg to 4mg weekly -- titrate slowly

Frequency: Once per week

Timing: Weekly SubQ injection, same day each week. Titrate very slowly -- standard Phase 3 schedule: 0.5mg weeks 1-4, 1mg weeks 5-8, 2mg weeks 9-12, 4mg weeks 13+. Research protocols typically use 1-4mg maintenance. Never rush titration -- GI adverse effects are dose-escalation dependent. Fed or fasted. Use the interactive dose calculator for unit calculations.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: WEIGHT MANAGEMENT

Description

Sia-31-c18 (single regulator) is a 31-amino acid glp-1 receptor agonist belonging to the peptide receptor modulator research series. it is a semaglutide-class single incretin agonist featuring a c18 fatty diacid (octadecanedioyl) side chain attached via a γ-glu-2x aeea linker at lys20, enabling albumin binding and extended half-life comparable to once-weekly dosing formats. the backbone closely mirrors the glp-1 incretin sequence with aib (alpha-aminoisobutyric acid) substitutions at key positions for dpp-4 resistance and enhanced receptor affinity. cas: 910463-68-2. structurally analogous in class to semaglutide. once-weekly subcutaneous injection. key reference literature: wilding et al. (nejm 2021) — once-weekly semaglutide in adults with overweight or obesity, 15% mean weight loss at 68 weeks; lincoff et al. (nejm 2023) — semaglutide and cardiovascular outcomes in obesity without diabetes; perkovic et al. (nejm 2024) — semaglutide effects on chronic kidney disease.

Specifications

Amount in Vial: 2mg

BAC Water: 1ml

Amount per Unit: 0.02mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2mg (12 to 100 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.02mg per unit

Category: WEIGHT MANAGEMENT

Description

Sia-31-c18 (single regulator) is a 31-amino acid glp-1 receptor agonist belonging to the peptide receptor modulator research series. it is a semaglutide-class single incretin agonist featuring a c18 fatty diacid (octadecanedioyl) side chain attached via a γ-glu-2x aeea linker at lys20, enabling albumin binding and extended half-life comparable to once-weekly dosing formats. the backbone closely mirrors the glp-1 incretin sequence with aib (alpha-aminoisobutyric acid) substitutions at key positions for dpp-4 resistance and enhanced receptor affinity. cas: 910463-68-2. structurally analogous in class to semaglutide. once-weekly subcutaneous injection. key reference literature: wilding et al. (nejm 2021) — once-weekly semaglutide in adults with overweight or obesity, 15% mean weight loss at 68 weeks; lincoff et al. (nejm 2023) — semaglutide and cardiovascular outcomes in obesity without diabetes; perkovic et al. (nejm 2024) — semaglutide effects on chronic kidney disease.

Specifications

Amount in Vial: 5mg

BAC Water: 1ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (5 to 50 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: WEIGHT MANAGEMENT

Description

Sia-31-c18 (single regulator) is a 31-amino acid glp-1 receptor agonist belonging to the peptide receptor modulator research series. it is a semaglutide-class single incretin agonist featuring a c18 fatty diacid (octadecanedioyl) side chain attached via a γ-glu-2x aeea linker at lys20, enabling albumin binding and extended half-life comparable to once-weekly dosing formats. the backbone closely mirrors the glp-1 incretin sequence with aib (alpha-aminoisobutyric acid) substitutions at key positions for dpp-4 resistance and enhanced receptor affinity. cas: 910463-68-2. structurally analogous in class to semaglutide. once-weekly subcutaneous injection. key reference literature: wilding et al. (nejm 2021) — once-weekly semaglutide in adults with overweight or obesity, 15% mean weight loss at 68 weeks; lincoff et al. (nejm 2023) — semaglutide and cardiovascular outcomes in obesity without diabetes; perkovic et al. (nejm 2024) — semaglutide effects on chronic kidney disease.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.05mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 250mcg to 2.5mg (5 to 50 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 250 MCG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.05mg per unit

Category: WEIGHT MANAGEMENT

Description

Dia-39-c20 (dual regulator) is a 39-amino acid dual incretin agonist belonging to the peptide receptor modulator research series. it simultaneously targets both the glp-1 receptor (glp-1r) and the gip receptor (gipr), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. the backbone is engineered from a gip-based scaffold with aib substitutions at positions 2 and 13 for dpp-4 resistance, and carries a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2023788-19-2. structurally analogous in class to tirzepatide. once-weekly subcutaneous injection. key reference literature: coskun et al. (cell metabolism 2022) — ly3437943 triple receptor agonist, discovery to clinical proof; urva et al. (lancet 2022) — phase 1b multiple-ascending dose trial; jastreboff et al. (nejm 2022) — tirzepatide once weekly for the treatment of obesity (surmount-1).

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 10mg (25 to 100 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Dia-39-c20 (dual regulator) is a 39-amino acid dual incretin agonist belonging to the peptide receptor modulator research series. it simultaneously targets both the glp-1 receptor (glp-1r) and the gip receptor (gipr), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. the backbone is engineered from a gip-based scaffold with aib substitutions at positions 2 and 13 for dpp-4 resistance, and carries a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2023788-19-2. structurally analogous in class to tirzepatide. once-weekly subcutaneous injection. key reference literature: coskun et al. (cell metabolism 2022) — ly3437943 triple receptor agonist, discovery to clinical proof; urva et al. (lancet 2022) — phase 1b multiple-ascending dose trial; jastreboff et al. (nejm 2022) — tirzepatide once weekly for the treatment of obesity (surmount-1).

Specifications

Amount in Vial: 30mg

BAC Water: 3ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 15mg (25 to 150 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Dia-39-c20 (dual regulator) is a 39-amino acid dual incretin agonist belonging to the peptide receptor modulator research series. it simultaneously targets both the glp-1 receptor (glp-1r) and the gip receptor (gipr), producing synergistic — not merely additive — metabolic effects through co-activation of overlapping downstream signaling pathways. the backbone is engineered from a gip-based scaffold with aib substitutions at positions 2 and 13 for dpp-4 resistance, and carries a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2023788-19-2. structurally analogous in class to tirzepatide. once-weekly subcutaneous injection. key reference literature: coskun et al. (cell metabolism 2022) — ly3437943 triple receptor agonist, discovery to clinical proof; urva et al. (lancet 2022) — phase 1b multiple-ascending dose trial; jastreboff et al. (nejm 2022) — tirzepatide once weekly for the treatment of obesity (surmount-1).

Specifications

Amount in Vial: 60mg

BAC Water: 3ml

Amount per Unit: 0.2mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2.5mg to 15mg (12.5 to 75 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2.5 MG — Titrate Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.2mg per unit

Category: WEIGHT MANAGEMENT

Description

Tia-39-c20 (triple regulator) is a 39-amino acid triple incretin agonist belonging to the peptide receptor modulator research series. it simultaneously activates three receptors: the glp-1 receptor (glp-1r), the gip receptor (gipr), and the glucagon receptor (gcgr). this triple mechanism adds glucagon receptor activation on top of dual incretin agonism — glucagon signaling directly increases resting energy expenditure and hepatic fat oxidation, producing weight loss effects beyond appetite suppression alone. features a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2381089-83-2. structurally analogous in class to retatrutide. once-weekly subcutaneous injection. key reference literature: jastreboff et al. (nejm 2023) — triple-hormone-receptor agonist phase 2 obesity trial (24.2% weight loss at 48 weeks); sanyal et al. (nature medicine 2024) — retatrutide for masld; rosenstock et al. (lancet 2023) — phase 2 retatrutide vs placebo.

Specifications

Amount in Vial: 10mg

BAC Water: 1ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2mg to 10mg (20 to 100 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2 MG — Titrate Very Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Tia-39-c20 (triple regulator) is a 39-amino acid triple incretin agonist belonging to the peptide receptor modulator research series. it simultaneously activates three receptors: the glp-1 receptor (glp-1r), the gip receptor (gipr), and the glucagon receptor (gcgr). this triple mechanism adds glucagon receptor activation on top of dual incretin agonism — glucagon signaling directly increases resting energy expenditure and hepatic fat oxidation, producing weight loss effects beyond appetite suppression alone. features a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2381089-83-2. structurally analogous in class to retatrutide. once-weekly subcutaneous injection. key reference literature: jastreboff et al. (nejm 2023) — triple-hormone-receptor agonist phase 2 obesity trial (24.2% weight loss at 48 weeks); sanyal et al. (nature medicine 2024) — retatrutide for masld; rosenstock et al. (lancet 2023) — phase 2 retatrutide vs placebo.

Specifications

Amount in Vial: 12mg

BAC Water: 1.2ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2mg to 12mg (20 to 120 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2 MG — Titrate Very Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: WEIGHT MANAGEMENT

Description

Tia-39-c20 (triple regulator) is a 39-amino acid triple incretin agonist belonging to the peptide receptor modulator research series. it simultaneously activates three receptors: the glp-1 receptor (glp-1r), the gip receptor (gipr), and the glucagon receptor (gcgr). this triple mechanism adds glucagon receptor activation on top of dual incretin agonism — glucagon signaling directly increases resting energy expenditure and hepatic fat oxidation, producing weight loss effects beyond appetite suppression alone. features a c20 fatty diacid (eicosanedioyl) side chain via a γ-glu-2x aeea linker for albumin binding and extended once-weekly half-life. cas: 2381089-83-2. structurally analogous in class to retatrutide. once-weekly subcutaneous injection. key reference literature: jastreboff et al. (nejm 2023) — triple-hormone-receptor agonist phase 2 obesity trial (24.2% weight loss at 48 weeks); sanyal et al. (nature medicine 2024) — retatrutide for masld; rosenstock et al. (lancet 2023) — phase 2 retatrutide vs placebo.

Specifications

Amount in Vial: 24mg

BAC Water: 2.4ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: titrate up from 2mg to 12mg (20 to 120 units)

Frequency: 1x per week

Timing: Same Day Every Week / Starting Dose Is 2 MG — Titrate Very Slowly

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Category: REPRODUCTIVE HEALTH

Description

Kisspeptin is a neuropeptide encoded by the kiss1 gene and the most potent known activator of the hypothalamic-pituitary-gonadal (hpg) axis. originally identified as a metastasis suppressor protein — hence the original name “metastin” — its role in reproductive endocrinology was established in 2003 when two independent research teams demonstrated that loss-of-function mutations in its receptor gpr54 (kiss1r) cause idiopathic hypogonadotropic hypogonadism: complete failure of puberty onset despite normal hypothalamic-pituitary anatomy. the most studied research form is kisspeptin-10 (kp-10), the c-terminal decapeptide that retains full receptor potency in a more stable, compact structure. kisspeptin neurons in the arcuate nucleus and anteroventral periventricular nucleus serve as the primary gatekeepers of gnrh pulsatility — they receive and integrate signals from sex steroids, leptin, ghrelin, and metabolic sensors, then generate synchronous pulses that drive the gnrh pulse generator. in male research subjects, a single subcutaneous injection of kp-10 triggers a measurable lh surge within 20–60 minutes, followed by serum testosterone increases within 2 hours. this makes kisspeptin uniquely valuable for hpg axis research: unlike direct lh or gnrh administration, kisspeptin activates the full upstream regulatory cascade without bypassing endogenous feedback. clinical research at imperial college london (dhillo et al. 2005 through comninos et al. 2017) has characterized its dose-response relationship, safety profile, and potential in hypogonadotropic hypogonadism. separate from hpg axis action, fmri studies have documented kisspeptin’s effects on limbic system processing — enhancing amygdala activation during sexual and emotional stimuli independent of any hormonal change. for research and educational purposes only. not fda-approved. consult a qualified healthcare professional.

Specifications

Amount in Vial: 5mg

BAC Water: 2ml

Amount per Unit: 0.025mg per unit

Injection Type: Subcutaneous

Recommended Dose: 100mcg to 300mcg (4 to 12 units)

Frequency: As needed

Timing: 30–60 minutes before activity. Pulsatile dosing (every 90 minutes if used repeatedly) best mimics physiological kisspeptin secretion patterns. Store reconstituted vial at 2–8°C, use within 30 days. Can be stacked with Gonadorelin for complementary HPG axis research.

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.025mg per unit

Category: LONGEVITY / MITOCHONDRIAL FUNCTION

Description

Nnmt (nicotinamide n-methyltransferase) inhibitor. research suggests support for fat cell metabolism, increased nad+ availability, and mitochondrial function. oral administration — no reconstitution required. research compound only.

Specifications

Amount in Vial: 50mg (oral capsules)

BAC Water: n/a — oral

Amount per Unit: 50mg per capsule

Injection Type: Oral

Recommended Dose: 50mg to 100mg (1 to 2 capsules)

Frequency: Daily

Timing: With or without food

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 50mg per capsule

Category: WEIGHT MANAGEMENT

Description

Fda-approved oral semaglutide (wegovy® pill) — the first oral glp-1 receptor agonist approved for chronic weight management in the united states (january 2026). uses a snac absorption enhancer to enable gastric mucosal absorption. oasis 2 clinical trial: 15.1% mean body weight reduction at 68 weeks. dose-escalation protocol: 7mg once daily for 4 weeks, then 14mg once daily. taken 30 minutes before the first food, drink, or other oral medication of the day with no more than 4 oz plain water. bioavailability approximately 1% compared to subcutaneous injection. over 3 million us prescriptions as of mid-2026. this is an fda-approved prescription pharmaceutical — not a research peptide. compounded oral semaglutide is not authorized under any current fda pathway.

Specifications

Amount in Vial: 7mg (30 tablets)

BAC Water: n/a

Amount per Unit: 7mg per tablet

Injection Type: Oral tablets

Recommended Dose: 7mg to 14mg (1 to 2 tablets)

Frequency: Daily

Timing: 30 minutes before first food or drink of the day, with 4 oz plain water only

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 7mg per tablet

Category: FAT LOSS / LEAN MUSCLE

Description

Err pan-agonist (errα/β/γ) that activates mitochondrial biogenesis programs, mimicking aerobic exercise at the molecular level. preclinical data shows 70% increase in endurance capacity and significant fat reduction in rodent models. no human clinical trials as of june 2026. early-stage research only. not fda approved. not available from licensed compounding pharmacies.

Specifications

Amount in Vial: 10mg

BAC Water: 2ml

Amount per Unit: 0.1mg per unit

Injection Type: Subcutaneous

Recommended Dose: 1mg to 5mg (10 to 50 units)

Frequency: 3x weekly

Timing: Fasted or pre-workout

Dose Calculator

Target Dose (mcg)

Volume (ml)

Units Needed

Based on 0.1mg per unit

Advanced Filters

2X Blend: Tesamorelin (10mg) / Ipamorelin (5mg)

2X Blend: CJC No DAC (5mg) / Ipamorelin (5mg)

2X Blend: Tesamorelin (5mg) / Ipamorelin (5mg)

3X Blend: Tesamorelin (5mg) / Ipamorelin (2.5mg) / MGF (500mcg)

4X Blend: Tesamorelin (5mg) / Ipamorelin (2.5mg) / GHRP-2 (5mg) / MGF (500mcg)

Semaglutide (GLP-1): 2mg

Semaglutide (GLP-1): 5mg

Semaglutide (GLP-1): 10mg

Semaglutide (GLP-1): 20mg

Tirzepatide (GLP-1/GIP): 10mg

Tirzepatide (GLP-1/GIP): 30mg

Tirzepatide (GLP-1/GIP): 50mg

Tirzepatide (GLP-1/GIP): 60mg

Retatrutide (GLP-1/GIP/Glucagon): 12mg

Retatrutide (GLP-1/GIP/Glucagon): 24mg

Survodutide: 6mg

AOD-9604: 5mg

Cagrilintide: 10mg

CJC1295 - No DAC: 10mg

CJC1295 - With DAC: 10mg

Tesamorelin: 5mg

Tesamorelin: 10mg

Sermorelin: 10mg

Sermorelin: 5mg

GHRP-2: 5mg

GHRP-6: 5mg

Ipamorelin: 10mg

Hexarelin: 5mg

HGH 10iu: 10IU

IGF1-LR3: 1mg